GILD.BA is trading flat at $48,640.00 today, June 24, 2026, consolidating gains after recent positive company news. - The European Commission granted marketing authorization for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer in patients ineligible for PD-1/PD-L1 inhibitors on June 23, 2026. - Positive investor sentiment continues to build around the HIV prevention candidate Yeztugo, following the FDA's acceptance of its sNDA for a once-weekly oral formulation on June 15, 2026. - While broader U.S. equity indices are trading modestly higher, GILD.BA's current flat trading follows significant movement on June 23, 2026 (+2.23%).